FDA Expands Spiriva Respimat Label

Inhalation spray now approved for age 6 and older

The FDA has approved Spiriva Respimat (tiotropium bromide, Boehringer Ingelheim), a steroid-free inhalation spray, for the long-term, once-daily maintenance treatment of asthma in patients 6 years of age and older. The agency approved the supplemental new drug application under a priority review designation.

Spiriva Respimat, which is delivered as two puffs once a day of 1.25 mcg per puff, is the only long-acting muscarinic antagonist (LAMA) product indicated for asthma. It was originally approved in September 2015 for the long-term, once-daily maintenance treatment of asthma in patients12 years of age and older.

The new approval was based on efficacy and safety data from the phase 2 and phase 3 UniTinA-asthma clinical development program, which included more than 6,000 patients worldwide, including 804 children (6 to 11 years of age).

More than 24 million people have asthma in the United States, including 6.3 million children younger than 18 years of age. Many children and adults continue to have uncontrolled asthma despite taking maintenance treatments. According to the Centers for Disease Control and Prevention, 50% of adults and more than 38% of children with asthma in the U.S. remain symptomatic despite maintenance treatment.

Source: Boehringer Ingelheim(link is external); February 16, 2017.

More Headlines

Pradaxa Superior to Warfarin in “Real World” Study

Efficacy and safety improved in patients with nonvalvular atrial fibrillation

Patient’s Death in Trial Raises Questions About Safety of Hemophilia Treatment Emicizumab

Potential blockbuster drug hits speed bump

FDA Clears Test to Help Manage Antibiotic Treatment for Lower Respiratory Tract Infections and Sepsis

Assay may help reduce unnecessary antibiotic use

Seven Ways Hospitals Can Beat Drug Shortages and Price Hikes

Pharmacy expert offers advice at Boston meeting

Drug Giants Turn to Leading Professors to Justify Hefty Price Tags

“Academics for hire” shape pricing debate

Liquid Pediatric Drugs Could Break the Bank; One Costs 775 Times the Generic Tablet

Asthma Drugs Could Prevent Deadly Form of Pneumonia

Researchers find new use for Accolate and Singulair

FDA Expands Revlimid Label

Treatment approved for post-HSCT maintenance in multiple myeloma patients

FDA Clears “Virtually Painless” Blood Collection Device

Walnut-sized device uses spring-loaded microneedles

The measures most often used today to assess care quality are process measures. Actual outcomes, of course, are harder to measure than whether a certain action has been taken—checking the feet of a patient with diabetes, for example. But many experts don’t think process measures get at the heart of quality.

HEDIS Is the Hassle That Became a Habit

After 25 years, the Healthcare Effectiveness Data and Information Set (HEDIS) is still criticized for focusing on process and taking up doctors’ time. But it has been incorporated into physicians’ workflow and may yet be instrumental in bringing about value-based care.

“Top 15” List Predicts Best-Selling Cancer Drugs in 2022

FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022.

The reviews are in! CMS Rating of Hospitals Gets 1.5 Stars

The problem, say hospitals and some analysts, is that rating hospital quality is not so straightforward. How a hospital delivers care is multifactorial and complex, they argue, so trying to cram that into a single score is misleading and can end up like rating a restaurant on its parking.

Is Step Therapy a Move In the Wrong Direction?

If insurers insist that doctors use older, lower-cost drugs first, the burden is on the health plan to respond to doctors’ request for different medications quickly, nimbly, and appropriately. But quick and nimble do not often describe insurers’ step-therapy efforts.

Far From Over: STDs Have Made a Comeback

Not too long ago, rates for sexually transmitted diseases (STDs) in the United States were at historic lows. Now they are at record highs, and many experts fear they will continue to climb because of meager funding of public health clinics and diminished sex education in schools.

For ED, the Doctor Is in But the Men Are Staying Away

Men’s health care changed dramatically after the FDA approved Pfizer’s blue, diamond-shaped Viagra. Suddenly men were interested in seeing their doctors if for only one reason. Now, with restrictions on what some call a lifestyle drug, other health problems go uncharted.

Joint Venture Health Plans May Give ACOs a Run for Their Money

Joint venture plans are starting to demonstrate their ability to implement clinical management and financial management reforms. A JV health plan replaces the offloading of financial risk by health plans to ill-equipped providers with an executive-level cost management committee stated jointly by the hospital and payer.

Fake Doctor Roams Boston Hospital

For several days, a middle-aged woman who claimed to be a doctor in training roamed the halls of Brigham and Women’s Hospital in Boston, dressed in scrubs, asking questions at a lecture, attending patient rounds, and observing surgical procedures, according to a report in the Boston Globe

Integrated Plans Fertile for Real-world Evidence

But most insurers are taking a wait-and-see attitude even though in some clinical areas, such as diabetes, real-world evidence (RWE) has been a true game-changer. Payers have a pessimistic view that RWE can help them. It doesn’t help that respected voices in health care agree.

Paul Lendner

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.

More Headlines

READ NEXT